Press kit · Last reviewed 2026-05-16

Press kit

For journalists, editorial offices and researchers: key figures, key claim, background sources and contact information.

Key claim of this dossier

The Dutch Protocol — a phased pathway with puberty blockers, cross-sex hormones and, later, surgery — rests on small observational Dutch studies without a control group (70 adolescents in 2011; 55 at the final measurement in 2014) and no randomised trials (source). According to the Cass Review, early versions of the Endocrine Society and WPATH guidelines then influenced almost all other guidelines (source). Independent evaluations since 2020 (NICE, SBU, Cass, Ukom) found the evidence weak; NICE rated it "very low certainty" for puberty blockers (source). In the Netherlands, the Health Council concluded on 30 June 2026 that Dutch care is carefully organised and saw no reason to change it, while rating the evidence low to very low (source).

Key figures

FigureContext
Before 1998First GnRHa treatment of a 13-year-old adolescent (Utrecht university hospital), published as a case report in 1998
1998First publication (Cohen-Kettenis & van Goozen) — case report
2006Formal protocol description (Delemarre & Cohen-Kettenis)
n = 70First follow-up study (de Vries 2011)
n = 55"Amsterdam study" (de Vries 2014) — final measurement of the first 70 patients
0RCTs supporting the protocol
93–98%Progression from puberty blockers to hormones in the studies Cass reviewed — blockers are "not buying time to think"
9%Pooled share of autism diagnoses among young people referred to gender clinics in nine countries (range 0–26%), according to Cass
~5,000Reported referrals to Tavistock GIDS (UK) in 2021/22; Cass notes this may include double counting
2024NHS England: puberty blockers no longer routinely available
2024-04Cass Review final report — international turn
2023-03SiRM report for ZonMw on the demand for transgender care in the Netherlands

Topics on which this site supplies sources

Tone and methodology

The site is a critical research project — not neutral, but source-faithful. Every claim has a Vancouver footnote. Independent systematic reviews weigh more heavily than publications from the original clinic. Full account at /methodology/. The position of Amsterdam UMC has its own, integrally reproduced page: /debate/response-vumc-amsterdam-umc/.

Contact

Stichting Genderinfo i.o. — editorial office. For substantive questions, background interviews or corrections: see /contact/. Response time for editorial enquiries: within 48 hours.

See also